Survodutide Dosage in 2026: Trial Doses and What Clinics Report
Survodutide (BI 456906) is Boehringer Ingelheim's investigational once-weekly injection that activates the glucagon and GLP-1 receptors. Its peer-reviewed phase 3 SYNCHRONIZE trials gave 3,600 or 6,000 mcg (3.6 or 6.0 mg) once weekly [1][2][3]; clinics that discuss it quote those doses rather than a protocol of their own [7][8]. It is not approved anywhere.
How is survodutide dosed?
Survodutide is dosed once weekly by subcutaneous injection, raised gradually over an extended period to limit side effects, to 3,600 or 6,000 mcg (3.6 or 6.0 mg) in its phase 3 trials [1][7]. Clinics that discuss survodutide quote those trial doses rather than a protocol of their own [7][8]. No trial has set a dose for use outside a study.
- Clinics: no clinic was found prescribing survodutide after searching 13 clinic sources, the eight largest telehealth companies among them; clinics describe it as available only inside clinical trials [7][8].
- What clinics quote: the phase 3 doses of 3,600 and 6,000 mcg (3.6 and 6.0 mg) weekly [7][8], or, on pages that predate phase 3, the phase 2 range of 600 to 4,800 mcg (4.8 mg) [9].
- The weight figure clinics quote varies with the analysis: one quotes 16.6% at 6,000 mcg (6 mg), the completers figure, and another 13.0%, the journal's treatment-regimen result [1][7][8].
- Frequency: once weekly in every source. No clinic publishes a step schedule, maximum dose or course length of its own [7][8][9].
The side effects are under What are the side effects of survodutide at each dose?, its legal status under Is survodutide legal?, and each trial’s doses under What do human studies show about survodutide dosing?
How is survodutide taken?
Survodutide was administered as a once-weekly subcutaneous injection in every published trial, with the dose raised step by step to the maintenance dose; in phase 3 the dose was adjusted up to 3,600 or 6,000 mcg (3.6 or 6.0 mg) [1][2]. Two formulation studies in healthy people compare a pre-filled syringe with a pen-like injector [10].
No approved label sets a missed-dose rule. The GLP-1 dose calculator converts a dose to syringe units for any concentration; it does not set a dose.
What are the side effects of survodutide at each dose?
Survodutide's side effects in its trials were mainly gastrointestinal: in the phase 3 obesity trial they affected 80.9% and 89.7% at 3,600 and 6,000 mcg (3.6 and 6.0 mg) vs 47.9% on placebo, typically mild to moderate, with no deaths [1]; in type 2 diabetes, 72.8% and 77.7% vs 38.6% [2]. No label lists contraindications.
- Fatty liver trial (phase 3): gastrointestinal events were the most frequent, commonly during dose escalation and generally mild to moderate [3].
- Phase 2 MASH trial: nausea 66% vs 23%, diarrhea 49% vs 23% and vomiting 41% vs 4% on placebo, with serious adverse events in 8% vs 7% [5].
- Phase 2 obesity trial: adverse events in 91% vs 75%, gastrointestinal in 75% vs 42%; about 60% completed treatment, similar on survodutide and placebo [4].
- Type 2 diabetes trial: adverse events in 77.8% vs 52.5% on placebo and 52.0% on semaglutide; the authors suggest slower dose escalation may reduce them [6].
What clinics report
Clinics describe the trial picture, gastrointestinal effects such as nausea, vomiting, diarrhea and constipation shared with other GLP-1 drugs, and report none of their own patients [7][8]. Phase 3 rates for heart rate, liver enzymes and serious adverse events are not in the abstracts read [1][2][3].
Is survodutide legal?
Survodutide is not approved in any country; it is an investigational drug with three published phase 3 trials [1][2][3]. Clinics describe it as experimental and available only inside clinical trials [7][8][9]; one says Boehringer had not filed for obesity in any major market as of November 2026 and expects a US application in late 2026 or early 2027 [7].
Compounding: a bulk substance can be compounded under section 503A only if it has a USP or NF monograph, is a component of an FDA-approved drug, or is on FDA's 503A bulks list. Survodutide meets none of the three, and it is not on the 503B bulks list either [11][12]. No FDA warning letter names it; the GLP-1 Solution letter of September 9, 2025 names retatrutide [13].
- Another clinic does not expect approval before 2027 or 2028 [14].
- Sport: survodutide is not named on the 2026 WADA Prohibited List, whose S0 class prohibits at all times any substance with no current approval for human therapeutic use [15].
- Research-grade survodutide, as sold by the vendors Prof. Peptide tracks, is labeled for laboratory research use only, is not the trial product and has no label behind it.
What do human studies show about survodutide dosing?
Survodutide's doses have been tested in randomized trials: three peer-reviewed phase 3 trials in 2026, in obesity, obesity with type 2 diabetes and fatty liver disease, used 3,600 and 6,000 mcg (3.6 and 6.0 mg) once weekly [1][2][3], after phase 2 trials of 600 to 6,000 mcg (6 mg) in obesity, MASH and type 2 diabetes [4][5][6].
No published phase 3 trial compares it with another obesity drug; the phase 2 type 2 diabetes trial included open-label semaglutide [6]. The phase 3 abstracts give no step-by-step escalation schedule [1][2].
SYNCHRONIZE-1 — obesity without diabetes
NCT06066515N Engl J Med 2026 [1]
Doses: 725 adults (241, 242 and 242) randomized to survodutide adjusted up to 3,600 or 6,000 mcg (3.6 or 6.0 mg) once weekly by subcutaneous injection, or placebo, with lifestyle counseling, for 76 weeks [1].
Result: Weight change −12.2% and −13.0% vs −5.4% on placebo (treatment-regimen analysis); at least 5% weight loss in 72.6% and 71.9% vs 46.3% [1].
Safety: Gastrointestinal adverse events in 80.9% and 89.7% vs 47.9% on placebo, typically mild to moderate, with no deaths [1].
SYNCHRONIZE-2 — obesity with type 2 diabetes
NCT06066528N Engl J Med 2026 [2]
Doses: 752 adults (250, 251 and 251), mean age 55.7, mean BMI 36.5, randomized to 3,600 or 6,000 mcg (3.6 or 6.0 mg) once weekly or placebo for 76 weeks [2].
Result: Weight change −8.2% and −9.8% vs −3.9% on placebo; at least 5% weight loss in 57.6% and 64.5% vs 35.1% [2].
Safety: Gastrointestinal adverse events in 72.8% and 77.7% vs 38.6% on placebo [2].
SYNCHRONIZE-MASLD — obesity with fatty liver disease
Nat Med 2026 [3]
Doses: 216 adults randomized 2:1 to 6,000 mcg (6.0 mg) once weekly (146) or placebo (70) for 48 weeks, in the US and Spain [3].
Result: Liver fat fell by at least 30% in 84.2% vs 24.3% on placebo (efficacy analysis; 68.5% vs 28.6% by treatment regimen); weight −8.7% vs −1.4% by treatment regimen [3].
Safety: Gastrointestinal events were the most frequent, commonly during dose escalation and generally mild to moderate [3].
Phase 2 — obesity
Lancet Diabetes Endocrinol 2024 [4]
Doses: 387 adults, 600 to 4,800 mcg (4.8 mg) once weekly or placebo for 46 weeks [4].
Result: Weight change up to −14.9% at 4,800 mcg (4.8 mg) vs −2.8% on placebo; a correction to the paper was published in 2026 [4].
Safety: Adverse events in 91% vs 75% on placebo, gastrointestinal in 75% vs 42%; about 60% completed the 46-week treatment period, similar on survodutide and placebo [4].
Phase 2 — MASH with fibrosis
N Engl J Med 2024 [5]
Doses: 293 people with MASH and fibrosis, 2,400 to 6,000 mcg (2.4–6.0 mg) once weekly or placebo [5].
Result: MASH improved in up to 62% vs 14% on placebo [5].
Safety: Nausea 66% vs 23%, diarrhea 49% vs 23% and vomiting 41% vs 4%; serious adverse events 8% vs 7% [5].
Phase 2 — type 2 diabetes
Diabetologia 2024 [6]
Doses: Weekly survodutide at a range of doses against placebo and open-label semaglutide [6].
Result: HbA1c fell by 0.91 to 1.71 points at 16 weeks [6].
Safety: Adverse events in 77.8% on survodutide, mainly gastrointestinal, vs 52.5% on placebo and 52.0% on semaglutide; the authors suggest slower dose escalation may reduce them [6].
FAQ
What is the dosage of survodutide?
How much weight do people lose on survodutide?
How often is survodutide dosed?
What are the side effects of survodutide?
Is survodutide approved or legal to prescribe?
References
- le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1). N Engl J Med. Published June 7, 2026. PMID 42253238. NCT06066515. https://pubmed.ncbi.nlm.nih.gov/42253238/
- Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2). N Engl J Med. Published October 1, 2026. PMID 42820639. NCT06066528. https://pubmed.ncbi.nlm.nih.gov/42820639/
- Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD). Nat Med. Published June 7, 2026. PMID 42252333. https://pubmed.ncbi.nlm.nih.gov/42252333/
- le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12:162–73. PMID 38330987; correction 2026, PMID 41421369. https://pubmed.ncbi.nlm.nih.gov/38330987/
- Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. PMID 38847460. https://pubmed.ncbi.nlm.nih.gov/38847460/
- Blüher M, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes. Diabetologia. 2024. PMID 38095657. https://pubmed.ncbi.nlm.nih.gov/38095657/
- Second Nature (US); medically reviewed; last updated November 2026; read November 5, 2026. Cited for its description of the trial schedule, its completers figure and its filing statement. https://www.secondnature.io/us/guides/current-health/survodutide-weight-loss-phase-3
- PepScribe, updated October 27, 2026; read November 5, 2026. Cited for its quotation of the phase 3 dose and result. https://pepscribe.com/learn/survodutide-vs-tirzepatide-reddit
- SimplyMeds Online (UK pharmacy). Read November 4, 2026. Cited for its status statement and its phase 2 dose range. https://www.simplymedsonline.co.uk/pages/survodutide-the-next-generation-of-dual-hormone-weight-loss.html
- ClinicalTrials.gov. NCT07413913 and NCT07768813: formulation studies (pre-filled syringe vs pen-like injector) in healthy people, as listed in Prof. Peptide’s research-lane search, November 5, 2026. https://clinicaltrials.gov/study/NCT07413913
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food and Drug Administration. 503B Bulk Drug Substances List. https://www.fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
- U.S. Food and Drug Administration. Warning Letter: GLP-1 Solution, reference 715883, September 9, 2025 (names retatrutide; does not name survodutide). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
- TrimRX, survodutide cost breakdown, May 2026; read November 4, 2026. Cited for its approval-timing statement. https://trimrx.com/blog/?p=90677
- World Anti-Doping Agency. The Prohibited List (2026). Valid January 1, 2026. https://www.wada-ama.org/en/prohibited-list
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- SurvodutideSurvodutide, a glucagon and GLP-1 receptor dual agonist: weight, fatty-liver and blood-sugar results from its phase 3 and phase 2 trials, side effects, legal status…
- How Is Semaglutide Dosed? Ozempic and Wegovy, ComparedSemaglutide has two injectable FDA labels — Ozempic and Wegovy — with different escalation lengths, maximums, and missed-dose windows.
- How Is TB-500 Dosed? What Studies and Clinics PublishTB-500, the 7-amino-acid fragment vendors sell, has not been trialed on its own.
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
Checked and updated
